187 related articles for article (PubMed ID: 11125366)
1. Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study.
Krege S; Rembrink V; Börgermann C; Otto T; Rübben H
J Urol; 2001 Jan; 165(1):67-71. PubMed ID: 11125366
[TBL] [Abstract][Full Text] [Related]
2. Combination of docetaxel, ifosfamide and cisplatin (DIP) as a potential salvage chemotherapy for metastatic urothelial carcinoma.
Kakutani S; Fukuhara H; Taguchi S; Nagata M; Niimi A; Hattori M; Miyazaki H; Fujimura T; Nakagawa T; Kume H; Igawa Y; Homma Y
Jpn J Clin Oncol; 2015 Mar; 45(3):281-5. PubMed ID: 25425701
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel.
Chen YM; Shih JF; Lee CS; Chen MC; Lin WC; Tsai CM; Perng RP
Lung Cancer; 2003 Feb; 39(2):209-14. PubMed ID: 12581575
[TBL] [Abstract][Full Text] [Related]
4. Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract.
Dodd PM; McCaffrey JA; Hilton S; Mazumdar M; Herr H; Kelly WK; Icasiano E; Boyle MG; Bajorin DF
J Clin Oncol; 2000 Feb; 18(4):840-6. PubMed ID: 10673526
[TBL] [Abstract][Full Text] [Related]
5. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules.
Bajorin DF; McCaffrey JA; Dodd PM; Hilton S; Mazumdar M; Kelly WK; Herr H; Scher HI; Icasiano E; Higgins G
Cancer; 2000 Apr; 88(7):1671-8. PubMed ID: 10738226
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative Oncology Group.
Dimopoulos MA; Bakoyannis C; Georgoulias V; Papadimitriou C; Moulopoulos LA; Deliveliotis C; Karayannis A; Varkarakis I; Aravantinos G; Zervas A; Pantazopoulos D; Fountzilas G; Bamias A; Kyriakakis Z; Anagnostopoulos A; Giannopoulos A; Kosmidis P
Ann Oncol; 1999 Nov; 10(11):1385-8. PubMed ID: 10631471
[TBL] [Abstract][Full Text] [Related]
7. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A
Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605
[TBL] [Abstract][Full Text] [Related]
8. Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial.
Bajorin DF; McCaffrey JA; Hilton S; Mazumdar M; Kelly WK; Scher HI; Spicer J; Herr H; Higgins G
J Clin Oncol; 1998 Aug; 16(8):2722-7. PubMed ID: 9704723
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial.
Pectasides D; Visvikis A; Aspropotamitis A; Halikia A; Karvounis N; Dimitriadis M; Athanassiou A
Eur J Cancer; 2000 Jan; 36(1):74-9. PubMed ID: 10741298
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study.
Ardavanis A; Tryfonopoulos D; Alexopoulos A; Kandylis C; Lainakis G; Rigatos G
Br J Cancer; 2005 Feb; 92(4):645-50. PubMed ID: 15685232
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study.
Sengeløv L; Kamby C; Lund B; Engelholm SA
J Clin Oncol; 1998 Oct; 16(10):3392-7. PubMed ID: 9779718
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel and ifosfamide in patients with advanced solid tumors: results of a phase I study.
Pronk LC; Schrijvers D; Schellens JH; de Bruijn EA; Planting AS; Locci-Tonelli D; Groult V; Verweij J; van Oosterom AT
Semin Oncol; 1998 Feb; 25(1 Suppl 2):23-8. PubMed ID: 9535208
[TBL] [Abstract][Full Text] [Related]
13. A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.
Kim YS; Lee SI; Park SH; Park S; Hwang IG; Lee SC; Sun JM; Lee J; Lim HY
Clin Genitourin Cancer; 2016 Feb; 14(1):76-81. PubMed ID: 26454620
[TBL] [Abstract][Full Text] [Related]
14. Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract.
Galsky MD; Iasonos A; Mironov S; Scattergood J; Donat SM; Bochner BH; Herr HW; Russo P; Boyle MG; Bajorin DF
Urology; 2007 Feb; 69(2):255-9. PubMed ID: 17320659
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of a second-line chemotherapy regimen with paclitaxel, ifosfamide and nedaplatin for metastatic urothelial carcinoma after failure of cisplatin-based chemotherapy.
Kobayashi K; Matsuyama H; Shimizu K; Fujii N; Inoue R; Yamamoto Y; Matsumoto H; Nagao K
Jpn J Clin Oncol; 2016 Aug; 46(8):775-80. PubMed ID: 27272172
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin, ifosfamide, methotrexate and vinblastine combination chemotherapy for metastatic urothelial cancer.
Kyriakakis Z; Dimopoulos MA; Kostakopoulos A; Karayiannis A; Sofras F; Zervas A; Giannopoulos A; Dimopoulos C
J Urol; 1997 Aug; 158(2):408-11. PubMed ID: 9224313
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group.
Dreicer R; Manola J; Schneider DJ; Schwerkoske JF; George CS; Roth BJ; Wilding G;
Cancer; 2003 Jun; 97(11):2743-7. PubMed ID: 12767086
[TBL] [Abstract][Full Text] [Related]
18. Combination chemotherapy of docetaxel, ifosfamide and cisplatin (DIP) in patients with metastatic urothelial cancer: a preliminary report.
Takahashi S; Suzuki M; Kume H; Matsumoto S; Okamoto N; Nishimatsu H; Tomita K; Kitamura T
Jpn J Clin Oncol; 2005 Feb; 35(2):79-83. PubMed ID: 15709091
[TBL] [Abstract][Full Text] [Related]
19. Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy.
Shinohara N; Harabayashi T; Suzuki S; Nagao K; Seki H; Murakumo M; Mitsuhashi K; Demura T; Nagamori S; Matsuyama H; Naito K; Nonomura K
Cancer Chemother Pharmacol; 2006 Sep; 58(3):402-7. PubMed ID: 16416335
[TBL] [Abstract][Full Text] [Related]
20. A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium.
Sweeney CJ; Williams SD; Finch DE; Bihrle R; Foster RS; Collins M; Fox S; Roth BJ
Cancer; 1999 Aug; 86(3):514-8. PubMed ID: 10430261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
